Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.56 |
| ▸ | HTR3B | O95264 | 5/20 | 0.56 |
| ▸ | HTR3A | P46098 | 5/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5628903 | 1.00 | CHRNA7 (0.57) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5630467 | 0.87 | CHRNA7 (0.58) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5630472 | 0.87 | CHRNA7 (0.58) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5628913 | 0.86 | CHEK1 (0.59) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5652057 | 0.86 | CHRNA7 (0.57) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5652052 | 0.86 | CHRNA7 (0.57) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5628917 | 0.86 | CHEK1 (0.59) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7438039 | 0.84 | — | — | |
| SCHEMBL5627973 | 0.83 | CHRNA7 (0.54) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5627977 | 0.83 | CHRNA7 (0.54) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191422-A1 | Nicotinic acetylcholine receptor ligands | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | claimed |
| EP-1699787-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | claimed |
| WO-2005061495-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| US-20070191422-A1 | Nicotinic acetylcholine receptor ligands | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| EP-1699787-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061495-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191422-A1 | Nicotinic acetylcholine receptor ligands | CHRNA2, CHRNA1, CHRNA6 | CHRNA7 4/4885HTR3E 322/4885HTR3B 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.